Clinical data spotlight on cardiac technologies

Boston Scientific (BSX) is back in focus after new clinical results for its FARAPULSE PFA and WATCHMAN LAAC platforms were presented at Heart Rhythm 2026, bringing real world atrial fibrillation and stroke risk reduction outcomes to investors.

Despite the encouraging clinical headlines and corporate activity around governance changes, institutional ownership updates and a new US$565.7m shelf registration, the stock’s recent share price performance has been weak, with a 30 day share price decline of 8.55% and a year to date share price decline of 40.27%. However, the 5 year total shareholder return of 35.95% points to a very different experience for longer term holders.

If you are looking beyond a single cardiology stock, it could be a useful moment to scan other medical technology opportunities through a healthcare focused AI stock screener such as 35 healthcare AI stocks

With the stock down 40.27% year to date, yet trading at a 51.93% discount to an indicated intrinsic value and 50.59% below analyst price targets, investors now face a simple question: Is this a reset opportunity, or is future growth already priced in?

Most Popular Narrative: 42.8% Undervalued

At a last close of $56.57 against a narrative fair value of $98.90, Boston Scientific is framed as materially undervalued, which puts extra weight on how that narrative thinks earnings, revenue and margins will evolve over time.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:

• Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we have seen in the recent price dips.
• Increased Debt Load: BSX is financing a significant portion of this deal (about $11 billion) with new debt. This has raised concerns about the company’s leverage, with projections hitting 3.3x adjusted EBITDA leverage by the end of 2026.

According to Bill_S, this valuation hangs on how quickly higher margin neurovascular and thrombectomy revenue can scale, and what kind of profit multiple the market is willing to pay if earnings growth tracks those assumptions instead of the more moderate forecasts now implied in consensus.

Result: Fair Value of $98.90 (UNDERVALUED)

However, this depends on Penumbra integration going smoothly and on higher leverage not limiting flexibility if clinical, regulatory, or pricing setbacks affect key product lines.

Next Steps

Given the mix of concern and optimism in this story, it makes sense to review the key positives yourself and stress test the assumptions that matter most to you, starting with the 5 key rewards

Looking for more investment ideas?

If this Boston Scientific story has sharpened your thinking, do not stop here. Broaden your watchlist and give yourself more options before the next move.

• Spot potential bargains early by scanning companies that look mispriced on quality and valuation using the 51 high quality undervalued stocks.
• Strengthen your downside protection by focusing on businesses with healthier finances through the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for less crowded opportunities by checking a screener containing 23 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.